





**LIFEStENT® Vascular Stent**

Deployment System	Catheter Length (cm)	Stent Diameter (mm)	Stent Length (mm)	Product code
	80	6	20	EX060201C
			30	EX060301C
			40	EX060401C
			60	EX060601C
			80	EX060801C
	7	20	EX070201C	
		30	EX070301C	
		40	EX070401C	
		60	EX070601C	
		80	EX070801C	


Deployment System	Catheter Length (cm)	Stent Diameter (mm)	Stent Length (mm)	Product code
	130	6	20	EX060203C
			30	EX060303C
			40	EX060403C
			60	EX060603C
			80	EX060803C
	7	20	EX070203C	
		30	EX070303C	
		40	EX070403C	
		60	EX070603C	
		80	EX070803C	


**LIFEStENT® XL Vascular Stent**

Deployment System	Catheter Length (cm)	Stent Diameter (mm)	Stent Length (mm)	Product code
	80	6	100	EX061001C
			120	EX061201C
			150	EX061501C
			170	EX061701C
			100	EX071001C
	7	120	EX071201C	
		150	EX071501C	
		170	EX071701C	

Deployment System	Catheter Length (cm)	Stent Diameter (mm)	Stent Length (mm)	Product code
	130	6	100	EX061003C
			120	EX061203C
			150	EX061503C
			170	EX061703C
			100	EX071003C
	7	120	EX071203C	
		150	EX071503C	
		170	EX071703C	

**LIFEStENT® SOLO™ Vascular Stent System**

Deployment System	Catheter Length (cm)	Stent Diameter (mm)	Stent Length (mm)	Product code
	80	6	200	EX062001L
		7	200	EX072001L

Deployment System	Catheter Length (cm)	Stent Diameter (mm)	Stent Length (mm)	Product code
	135	6	200	EX062003L
		7	200	EX072003L

For all product codes: 0.035" Guidewire, 6F Catheter System.

**BARD® LIFEStENT® Vascular Stent Systems**

**Prescriptive Information:** Prior to use, please see the complete "Directions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events and Operator's Instructions.

**Indications:** The LIFEStENT® Vascular Stent System is intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions in the native superficial femoral artery (SFA) and proximal popliteal artery.

**Contraindications:** The LIFEStENT® Vascular Stent System is contraindicated for use in patients with a known hypersensitivity to nitinol (nickel, titanium), and tantalum. Patients who cannot receive recommended antiplatelet and/or anti-coagulation therapy. Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or stent delivery system. Patients with a target lesion with a large amount of adjacent acute or subacute thrombus.

**Warnings:** The use of this device carries the risks associated with peripheral vascular stenting, including vessel dissection and/or bleeding events.

**Precautions:** Stent fractures were noted to be an uncommon event in the RESILIENT trial. Stent fractures may occur with the use of overlapping stents; however there was no correlation between stent fractures and the number of stents implanted in the RESILIENT trial. Fractures may occur in SFA or popliteal segments that undergo significant motion, particularly in areas with severe angulation and tortuosity. Care should also be taken when deploying the stent as manipulation of the delivery system may, in rare instances, lead to stent elongation and subsequent stent fracture. The long-term clinical implications of these stent fractures have not yet been established.

**Potential Adverse Events:** Potential adverse events which may be associated with the use of a stent in the SFA and proximal popliteal arteries include, but are not limited to:

- Allergic/anaphylactoid reaction • Amputation • Aneurysm • Arterial occlusion/thrombus • By-pass Surgery • Embolization • Hemorrhage/bleeding • Pseudoaneurysm • Renal failure • Restenosis • Stent Fracture • Stent Migration

**AUSTRIA Bard Medica SA**  
Thaliastrasse 125A/1/5, 1160 Wien, Austria  
Tel: +43 14 949130 Fax: +43 14 94913030

**BENELUX Bard Benelux n.v.**  
Hagelberg 2, 2250 Olen, Belgium  
Tel: +32 14 286950 Fax: +32 14 286955

**CZECH REPUBLIC Bard Czech Republic s.r.o.**  
Taborska 619, 140 00 Prague, Czech Republic  
Tel: +420 242 408630 Fax: +420 242 410185

**FRANCE Bard France SAS**  
Av. Joseph Kessel 164-166, Parkile P14,  
78960 Voisins-le-Bretonneux, France  
Tel: +33 1 39305858 Fax: +33 1 39305859

**GERMANY C. R. Bard GmbH**  
Wachhausstrasse 6, 76227 Karlsruhe, Germany  
Tel: +49 721 94450 Fax: +49 721 9445111

**GREECE Bard Hellas SA**  
22, Alkiviadou St & 72, Vouliagmenis Av,  
16675 Glyfada, Greece  
Tel: +30 210 9690770 Fax: +30 210 9628810

**IRELAND Bard Ltd**  
Arena House, Arena Road,  
Sandyford, Dublin 18, Ireland  
Tel: +353 121 307016 Fax: +353 121 30604

**ITALY Bard S.p.A.**  
Via Cina 444, 00144 Roma, Italy  
Tel: +39 06 524931 Fax: +39 06 5295852

**NORDIC Bard Norden AB**  
Karbingatan 22, 254 67 Helsingborg, Sweden  
Tel: +46 42 386000 Fax: +46 42 386010

**POLAND Bard Poland sp.z.o.o.**  
ul. Cybernetyki 7B, 02-677 Warsaw, Poland  
Tel: +48 22 3210930 Fax: +48 22 3210938

**PORTUGAL C. R. Bard Portugal, LDA**  
Rua Castilho 13D-2A, 1250-066 Lisboa, Portugal  
Tel: +351 21 3190330 Fax: +351 21 3190339

**SPAIN Bard de Espana S.A.**  
Avda. Diagonal 652-656, Edificio A, 4a planta,  
08034 Barcelona, Spain  
Tel: +34 93 2537800 Fax: +34 93 2537834


**SWITZERLAND Bard Medica SA**  
Seestrasse 64, 8942 Oberrieden/Zürich, Switzerland  
Tel: +41 44 7225360 Fax: +41 44 7225370

**UK Bard Limited**  
Forest House, Tilgate Forest Business Park,  
Brighton Road, Crawley, West Sussex RH11 9BP, UK  
Tel: +44 1293 527888 Fax: +44 1293 552428

# LIFEStENT®

## Vascular Stent Systems

Advanced Helical Design. Unmatched SFA Outcomes.



**only**  
**FDA APPROVED**

- SFA and Proximal Popliteal Artery
- Vessel Diameters of 4.0 - 6.5 mm




- Helical Strut
- Helical Bridge


## TRUE HELICAL

- Engineered for Bending, Compression, Torsion
- Dynamic Vessel Conformability

### STENT FRACTURE RATE



The low fracture rate suggests the flexible helical design may afford some degree of fracture resistance.




- Improved Lesion Coverage With a Single Stent up to 200 mm


200 mm



### PRIMARY PATENCY RATE



### FREEDOM FROM TLR



### RESILIENT

A prospective, randomized, controlled, multi-center study comparing LIFESTENT<sup>®</sup> Vascular Stent vs. Angioplasty alone in lesions of the SFA and/or proximal popliteal artery.

### TRIAL OVERVIEW

- 206 patients enrolled: 72 in PTA group, 134 in PTA and LIFESTENT<sup>®</sup> Vascular Stent group
- 24 study sites in United States and Europe
- Symptomatic *De Novo* or Restenosed Lesions
- Average stented length of 99 mm